Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling historical survival rates.

ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design reveals...

CMO location drives site selection for Parkinsonian imaging trial, requiring geographic proximity to manufacturing over patient populations.

Johnson & Johnson sells Laminar program to newly formed Jaguar LAA for left atrial appendage closure technology development and...

Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC after demonstrating superior efficacy and manageable safety in...

Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial, showing OS benefit over topotecan in...

FDA's finalized psychedelic guidance rewrites the rules on blinding, informed consent, and session monitoring, and the NEJM's September 2026...

Ennov appoints Dr. Oxana Pickeral as Chief Executive Officer, succeeding 27-year founder Olivier Pâris amid accelerating regulatory compliance demand.

PerZeption receives NEI SBIR grant to develop a photostress recovery test for AMD on tablet hardware, aiming to detect...

Lyell completes LYL273 manufacturing transfer to its Bothell facility, though the Phase 1/2 colorectal cancer trial now faces enrollment...